Table 2 Main analysis; adjusted Third Dose Effectiveness (VE) against SARS-Cov2 infection.

From: Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Exposure Groups/Booster Period

Cases

Controls

Adjusted Third Dose VE (%) for SARS-Cov2 Infection (CI 95%)

Aug. 2021 (−5)‡

21,777

21,234

Reference

Sep. 2021 (−4)‡

25,419

24,432

3.6 (0.6, 6.5)

Oct. 2021 (−3)‡

7050

7773

16.5(13, 19.9)

Nov. 2021 (−2)‡

792

1156

35.7(29.8, 41.2)

Dec. 2021 (−1)‡

421

864

53.4(47.7, 58.6)

 

55459

55459

 
  1. ‡ Denotes the months prior to the outcome period. Therefore, those who received the booster in October 2021, received the third dose 3 months prior to the outcome period.
  2. VE was defined as 100%*[1-(Odds Ratio)] for each of the month-since-vaccination categories.
  3. ORs were estimated with conditional logistic regression on a 1:1 matched dataset, and adjusted for comorbidities.
Back to article page